139 related articles for article (PubMed ID: 25455720)
1. Severe infections in patients with autoimmune diseases treated with cyclophosphamide.
Cavallasca JA; Costa CA; Maliandi Mdel R; Contini LE; Fernandez de Carrera E; Musuruana JL
Reumatol Clin; 2015; 11(4):221-3. PubMed ID: 25455720
[TBL] [Abstract][Full Text] [Related]
2. Cyclophosphamide: As bad as its reputation? Long-term single centre experience of cyclophosphamide side effects in the treatment of systemic autoimmune diseases.
Dan D; Fischer R; Adler S; Förger F; Villiger PM
Swiss Med Wkly; 2014; 144():w14030. PubMed ID: 25341028
[TBL] [Abstract][Full Text] [Related]
3. Risk factors for serious infection during treatment with cyclophosphamide and high-dose corticosteroids for systemic lupus erythematosus.
Pryor BD; Bologna SG; Kahl LE
Arthritis Rheum; 1996 Sep; 39(9):1475-82. PubMed ID: 8814058
[TBL] [Abstract][Full Text] [Related]
4. Side-effects of intravenous cyclophosphamide pulse therapy.
Martin F; Lauwerys B; Lefèbvre C; Devogelaer JP; Houssiau FA
Lupus; 1997; 6(3):254-7. PubMed ID: 9104732
[TBL] [Abstract][Full Text] [Related]
5. Zoster after Cyclophosphamide for Systemic Lupus Erythematosus or Vasculitis: Incidence, Risk Factors, and Effect of Antiviral Prophylaxis.
Garnier C; Ribes D; Chauveau D; Huart A; Pugnet G; Adoue D; Prevot G; Alric L; Delobel P; Derumeaux H; Mengelle C; Sailler L; Moulis G
J Rheumatol; 2018 Nov; 45(11):1541-1548. PubMed ID: 30008461
[TBL] [Abstract][Full Text] [Related]
6. Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide.
Mok CC; Ying KY; Ng WL; Lee KW; To CH; Lau CS; Wong RW; Au TC
Am J Med; 2006 Apr; 119(4):355.e25-33. PubMed ID: 16564783
[TBL] [Abstract][Full Text] [Related]
7. Severe infections in plasmapheresis-treated systemic lupus erythematosus.
Aringer M; Smolen JS; Graninger WB
Arthritis Rheum; 1998 Mar; 41(3):414-20. PubMed ID: 9506568
[TBL] [Abstract][Full Text] [Related]
8. Upregulation of antiphospholipid antibodies following cyclophosphamide therapy in patients with systemic lupus erythematosus.
Vlachoyiannopoulos PG; Toya SP; Katsifis G; Zintzaras E; Tzioufas AG; Moutsopoulos HM
J Rheumatol; 2008 Sep; 35(9):1768-75. PubMed ID: 18634157
[TBL] [Abstract][Full Text] [Related]
9. Comparison of low-dose intravenous cyclophosphamide with oral mycophenolate mofetil in the treatment of lupus nephritis.
Rathi M; Goyal A; Jaryal A; Sharma A; Gupta PK; Ramachandran R; Kumar V; Kohli HS; Sakhuja V; Jha V; Gupta KL
Kidney Int; 2016 Jan; 89(1):235-42. PubMed ID: 26489028
[TBL] [Abstract][Full Text] [Related]
10. Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension.
Sanchez O; Sitbon O; Jaïs X; Simonneau G; Humbert M
Chest; 2006 Jul; 130(1):182-9. PubMed ID: 16840400
[TBL] [Abstract][Full Text] [Related]
11. Mycophenolate mofetil vs cyclophosphamide therapy for patients with diffuse proliferative lupus nephritis.
Hu W; Liu Z; Chen H; Tang Z; Wang Q; Shen K; Li L
Chin Med J (Engl); 2002 May; 115(5):705-9. PubMed ID: 12133539
[TBL] [Abstract][Full Text] [Related]
12. Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy.
Mok CC; Lau CS; Wong RW
Arthritis Rheum; 1998 May; 41(5):831-7. PubMed ID: 9588734
[TBL] [Abstract][Full Text] [Related]
13. [Treatment of systemic diseases with pulse cyclophosphamide: 15 cases].
Amoura Z; Choukroun G; Royer I; Gayraud M; Guillevin L
Ann Med Interne (Paris); 1990; 141(5):416-20. PubMed ID: 2256584
[TBL] [Abstract][Full Text] [Related]
14. Cyclophosphamide in combination with glucocorticoids for severe neuropsychiatric systemic lupus erythematosus: a retrospective, observational two-centre study.
Fanouriakis A; Pamfil C; Sidiropoulos P; Damian L; Flestea A; Gusetu G; Rednic S; Bertsias G; Boumpas DT
Lupus; 2016 May; 25(6):627-36. PubMed ID: 26692040
[TBL] [Abstract][Full Text] [Related]
15. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide.
Houssiau FA; Vasconcelos C; D'Cruz D; Sebastiani GD; Garrido Ed Ede R; Danieli MG; Abramovicz D; Blockmans D; Mathieu A; Direskeneli H; Galeazzi M; Gül A; Levy Y; Petera P; Popovic R; Petrovic R; Sinico RA; Cattaneo R; Font J; Depresseux G; Cosyns JP; Cervera R
Arthritis Rheum; 2002 Aug; 46(8):2121-31. PubMed ID: 12209517
[TBL] [Abstract][Full Text] [Related]
16. Cyclophosphamide as alternative immunosuppressive therapy for autoimmune hepatitis--report of three cases.
Kanzler S; Gerken G; Dienes HP; Meyer zum Büschenfelde KH; Lohse AW
Z Gastroenterol; 1997 Jul; 35(7):571-8. PubMed ID: 9273991
[TBL] [Abstract][Full Text] [Related]
17. Lupus mesenteric vasculitis: clinical features and associated factors for the recurrence and prognosis of disease.
Yuan S; Ye Y; Chen D; Qiu Q; Zhan Z; Lian F; Li H; Liang L; Xu H; Yang X
Semin Arthritis Rheum; 2014 Jun; 43(6):759-66. PubMed ID: 24332116
[TBL] [Abstract][Full Text] [Related]
18. General adverse response to cyclophosphamide in Chinese patients with systemic autoimmune diseases in recent decade—a single-center retrospective study.
Li J; Dai G; Zhang Z
Clin Rheumatol; 2015 Feb; 34(2):273-8. PubMed ID: 25053381
[TBL] [Abstract][Full Text] [Related]
19. Clinical evaluation of patients with inflammatory connective tissue diseases complicated by cytomegalovirus antigenemia.
Yoda Y; Hanaoka R; Ide H; Isozaki T; Matsunawa M; Yajima N; Shiozawa F; Miwa Y; Negishi M; Kasama T
Mod Rheumatol; 2006; 16(3):137-42. PubMed ID: 16767551
[TBL] [Abstract][Full Text] [Related]
20. Rituximab vs mycophenolate and vs cyclophosphamide pulses for induction therapy of active lupus nephritis: a clinical observational study.
Moroni G; Raffiotta F; Trezzi B; Giglio E; Mezzina N; Del Papa N; Meroni P; Messa P; Sinico AR
Rheumatology (Oxford); 2014 Sep; 53(9):1570-7. PubMed ID: 24505125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
